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NEGATIVE PRESSURE WOUND THERAPY ASSOCIATION
WITH REDUCED OCCURRENCE OF DIABETIC FOOT ULCER
AMPUTATIONS:A RETROSPECTIVE STUDY OF PAYOR CLAIMS
DATA
Frykberg RC1,Williams DV2, Keith MS3
1Carl T. Hayden VA Medical Center, Phoenix, AZ, USA, 2Milliman
Consultants, Windsor, CT, USA, 3KCI USA, Inc, San Antonio,TX, USA
OBJECTIVE: To evaluate the relative occurrence of amputations
for diabetic foot ulcer (DFU) patients treated with negative pres-
sure wound therapy (NPWT), as delivered by Vacuum-Assisted
Closure Therapy, compared to patients treated with traditional
wound therapies (control group) in two different patient popu-
lations. METHODS: A retrospective database analysis using
administrative data from two different sources was completed.
Data sources included: 1) a commercial payor source including
2002–2003 claims and 2) a random 5% sample of 2003
Medicare claims (CMS). ICD-9-CM diagnosis and procedure
codes, CPT-4 and HCPCS codes were used to identify NPWT
and control patients. Risk adjustment procedures were employed
to account for patient acuity differences between the control and
NPWT samples. RESULTS: The commercial dataset yielded over
3500 patients meeting the study criteria while the Medicare
dataset included over 12,700 patients. This retrospective analy-
sis demonstrated that the proportion of patients with an ampu-
tation was lower following treatment with NPWT when
compared to the control group. This ﬁnding was consistent for
the commercial and Medicare datasets. From the commercial
dataset population, NPWT was associated with up to a 34%
lower amputation occurrence compared to the control group. 
(p = 0.09) In the Medicare population, the DFU risk-adjusted
amputation percentages were 16.6% for control and 10.8% for
NPWT groups (p = 0.007). Additionally, higher severity patients
(categorized based on debridement depth) experienced fewer
amputations when treated with NPWT vs. control therapies.
CONCLUSIONS: This retrospective analysis is the ﬁrst to assess
the relationship of NPWT to DFU amputations using two large
datasets. In this analysis, the results from two distinct datasets
consistently suggest that diabetic foot ulcer patients treated with
NPWT experienced a lower incidence of amputations compared
to control patients. NPWT may play an important role in the
incidence of diabetic-related amputation events that lead to sig-
niﬁcant economic and quality of life implications.
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FACTORS ASSOCIATED WITH DIABETES CONTROL IN A
LATINO POPULATION USING A HEALTH BEHAVIOR MODEL
APPROACH
Aranda GA, Johnson KA,Wu J
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To determine the prevalence of diabetes, diabetes
control, and risk factors associated with type-2 diabetes control
in a sample of adult Latinos. METHODS: Data were obtained
from the Los Angeles Latino Eye Study (LALES), a large popu-
lation-based survey of eye disease in Latinos greater than 40
years of age including a clinical evaluation and home survey
questionnaire. All participants were stratiﬁed by diabetes status
and compared with non-diabetics. The participants with diabetes
were then stratiﬁed by diabetes control per the American Dia-
betes Association (ADA) guidelines. A multivariate logistic
regression analysis was conducted to identify risk factors asso-
ciated with diabetes control. The univariate and multivariate
analyses utilized components of the health behavior model,
which included predisposing, enabling and need characteristics.
RESULTS: Data for 6980 participants were evaluated. There
were 1321 participants identiﬁed with diabetes resulting in a
prevalence of 19%. Of all participants, 41.9% were males,
27.8% were single and 65.5% had insurance coverage. 3.8% of
the participants without a diabetes diagnosis had clinical values
(A1C) above the diabetic goal, indicating possible diabetes. Of
the diabetics, only 36% were controlled. Diabetics were older
(57.8 vs. 53.9; p < 0.0001) and insured (73.9% vs. 64.2%; p <
0.0001). 6.8% of the diabetics were untreated, 72.7% were
using oral anti-diabetic medication, 21.3% were using insulin,
57.4% were using diet and 15.3% were using a combination 
of oral medication and insulin. Logistic regression analysis 
(Likelihood X2 = 143.5, p < 0.0001) showed that lack of 
problems getting healthcare when needed, higher education,
lower Body Mass Index (BMI) and advancing age were associ-
ated with diabetes control. CONCLUSIONS: Though severity of
disease and medication adherence were not assessed, problems
getting care and a higher BMI were associated with poor dia-
betes control in this Latino population. While some diabetics in
this population are untreated, many are not meeting ADA goals
or remain undiagnosed.
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TYPE 2 DIABETES PATIENTS
Balkrishnan R1, Shenolikar R1, Rajagopalan R2, Camacho F3,
Anderson RT3
1The Ohio State University College of Pharmacy, Columbus, OH,
USA, 2Takeda Pharmaceuticals North America Inc, Lincolnshire, IL,
USA, 3Wake Forest University School of Medicine, Winston Salem,
NC, USA
OBJECTIVES: Outcomes in patients with type 2 diabetes may
vary depending on the antidiabetic medication used. This study
compared differences in total health care costs, medication
adherence, and persistence in patients with type 2 diabetes
enrolled in the North Carolina Medicaid Program that were
newly started on thiazolidinedione (TZD) therapy with patients
starting other oral antidiabetics (OAD) during the same period.
METHODS: A total of 2660 patients newly starting TZD
therapy between July 2001 and December 2003 were compared
to 2050 patients starting other oral antidiabetic medication for
health care costs and outcomes in the post-medication start year.
Multivariate regression techniques incorporating health care uti-
lization in the year prior to start of new therapy were utilized to
determine the net cost impact of one therapy versus the other.
RESULTS: The mean age of the TZD group was signiﬁcantly
higher as compared to OAD group (p < 0.05). Total number of
prescription reﬁlls was signiﬁcantly higher with TZD than OAD
(p < 0.05). Other baseline characteristics were similar across the
two groups. The TZD cohort had signiﬁcantly higher persistence
rates as well as adherence rates compared to OAD in the 2nd
year (p < 0.01). Multiple regression analyses found that patients
starting TZD have better treatment persistence in the post-med-
ication start year compared to patients starting other oral antidi-
abetic agents. (4% increase in therapy persistence index, P <
0.001). In addition, patients starting TZDs had 19% lower total
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annual health care costs (P < 0.01) compared to patients start-
ing other oral antidiabetic agents. CONCLUSIONS: Introduc-
tion of thiazolidinedione therapy in a Medicaid-enrolled type 2
diabetic population was associated with signiﬁcantly greater
treatment persistence and lower healthcare costs in the post-start
year compared to patients starting other oral antidiabetic agents.
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ECONOMIC IMPACT OF AUGMENTATION THERAPY IN TYPE 2
DIABETES PATIENTS INITIATED ON SULFONYLUREAS: A
RETROSPECTIVE COHORT ANALYSIS
Kalsekar ID, Latran M
Butler University, Indianapolis, IN, USA
OBJECTIVE: To assess the economic impact of augmentation
therapy [thiazolidinediones (TZDs) or metformin] in type 2 dia-
betes patients who initiated mono-therapy with sulfonylurea.
METHODS: A retrospective cohort design was used to meet the
study objective. Patients newly diagnosed with type 2 diabetes
and initiating therapy with sulfonylurea were identiﬁed during
the four-year period (1998–2001) from a Medicaid claims data-
base. These patients were then followed till they augmented
therapy by adding another oral hypoglycemic agent (TZDs or
metformin) to their regimen. The date of the ﬁrst prescription
for a TZD or metformin was treated as the index date and type
2 diabetes-related costs in the 12-month follow-up period were
assessed. Semi-logarithmic OLS models were used to estimate the
impact of therapy on total diabetes-related costs. Costs were also
examined separately in terms of diabetes-related Emergency
Room (ER)/hospitalization, outpatient and prescription costs
using appropriate two-part models. RESULTS: The ﬁnal cohort
consisted of 298 type 2 diabetes patients who initiated mono-
therapy with sulfonylureas and augmented with either TZDs (n
= 96) or metformin (n = 202). Results of the semi-log OLS model
indicated that patients augmenting sulfonylurea therapy with
metformin incurred 33.27% lower total diabetes-related costs as
compared to those augmenting therapy with TZDs (p < 0.001).
Further breakdown of the costs indicated that there were no sig-
niﬁcant differences in diabetes-related ER/Hospitalization and
outpatient costs between the two groups. However, diabetes-
related prescription costs were 45.47% lower for patients aug-
menting with metformin as compared those augmenting with
TZDs (p < 0.001). CONCLUSION: Patients with type 2 diabetes
initiated on mono-therapy with sulfonylureas and augmenting
with metformin have signiﬁcantly lower type 2 diabetes-related
costs as compared to those augmenting with TZDs, primarily
due to lower prescription costs. The study results can aid in
making important formulary decisions and developing treatment
algorithms for management of type 2 diabetes.
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PHARMACOECONOMIC ANALYSIS OF ANGIOTENSIN-
CONVERTING ENZYME INHIBITORS IN TYPE II DIABETICS
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OBJECTIVES: To determine the cost-effectiveness of adding
angiotensin-converting enzyme inhibitor (ACEI) therapy at
normo-, micro-, and macro-albuminuric stages in Type II dia-
betics. METHODS: We employed a recently published Markov
model depicting nephropathy and cardiovascular disease (CVD)
events among diabetics. Probabilities and costs were from the 
literature. We incorporated a health payer perspective, direct
medical costs with 3% discounting, 1 year cycles, and a 6 year
time horizon. Endpoints were cost/life-year gained (LYG),
cost/death avoided, cost/CVD event averted, cost/patient pre-
vented from dialysis, and cost/composite endpoint (death, CVD
event, dialysis) averted. End-stage renal disease (ESRD) was
excluded from baseline; we assumed these patients would
already be on ACEIs unless contraindicated. We used informa-
tion from the New Mexico Medicaid diabetic population to
ascertain prevalence of each stage of nephropathy and mean age
(68.8 years). The base case included the average cost for ACEIs
at target doses. RESULTS: ACEI treatment is dominant when
initiated in normoalbuminuric patients. Starting ACEI therapy
at microalbuminuria provides incremental cost-effectiveness
ratios (ICERs) of $624.21, $28,000.43, $129.85, and $13.21 per
avoidance of CVD event, dialysis event, death, and LYG, respec-
tively. Waiting until macroalbuminuria causes ACEI therapy to
be dominated for CVD and dialysis events due to lower survival
with the no ACEI alternative. ICERs for death and LYG are
$431.28 and $43.87, respectively. In one-way sensitivity analy-
ses the model was sensitive to ACEI costs and insensitive to dial-
ysis costs. For two-way sensitivity analyses we incorporated
ACEI and dialysis costs and assumed ACEIs further attenuate
the progression from macroalbuminuria to ESRD by 20%.
Across all stages of nephropathy for each cost variation, cost per
additional dialysis event avoided was most impacted in this
analysis. CONCLUSIONS: In most patients, ACEIs should be
initiated upon diagnosis of Type II diabetes to prevent higher
healthcare costs due to more events in the future.
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PATIENTS WITH DIABETES: RESULTS FROM A
COMPUTERIZED SIMULATION MODEL
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The increased costs of intensive early management of diabetes
may be offset by a reduction in future complications. As com-
plications of diabetes have been shown to signiﬁcantly contribute
to health care costs, computer simulation models are increasingly
being used to evaluate the likely impact of interventions on the
progression of diabetes as well as the health and economic con-
sequences interventions are likely to accrue over a patient’s life-
time. OBJECTIVES: Stimulate long-term costs and consequences
of an observational 18-month nurse-led multifaceted diabetes
management program aimed at the patient, the health care
providers and the health care system. METHODS: We con-
ducted a cost-effectiveness analysis based on patient-level data
from an observational study involving 404 patients with dia-
betes. Changes in intermediate outcomes (e.g. HbA1c, blood
pressure, cholesterol, and smoking status) at the end of the inter-
vention period were measured and used as risk factors in a Cana-
dian-speciﬁc probabilistic discrete-event model to simulate the
mean difference in cost and expected quality-adjusted life years
(QALYs). Incremental cost-effectiveness ratios were calculated
based on the net cost of health care resources associated with the
program and on effectiveness estimated over a patient’s lifetime.
In the base case, the cost-effectiveness ratio was calculated
assuming the effect of the intervention continued for 1 year using
a discount rate of 3%. RESULTS: The multifaceted diabetes
management program on average reduced HbA1c by 1% (SD
2.3%), systolic blood pressure by 1.4mmHg (SD 21.3), total to
HDL cholesterol ratio by 0.69 (SD 1.30). The incremental cost
